Qiagen has benefited from unexpected tailwinds due to COVID-19 testing and envisions post-pandemic growth with recently acquired NeuMoDx as a key contributor.
The company said clinical services revenues and diagnostic testing volumes rose during the quarter, but that PAMA continued to negatively affect reimbursements.
The GenFlex is a sample-to-result molecular diagnostic platform that includes sample collection, processing, amplification, and detection, the company said.